Prelude Therapeutics Inc expected to post a loss of 61  cents a share - Earnings Preview

Prelude Therapeutics Incorporated

08/08/2022 18:04

* Prelude Therapeutics Inc  PRLD.OQ   PRLD.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 10 (estimated). 
    * ​Refinitiv's mean analyst estimate for Prelude
Therapeutics Inc
is for a loss of 61 cents per share. For the same quarter last
year, the company reported a loss of 58 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Prelude
Therapeutics Inc is $9​, above​ its last closing price of $6.17.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.65       -0.65      -0.63     Beat    3.1
 Dec. 31 2022  -0.67       -0.68      -0.71     Missed  -4
 Sep. 30 2021  -0.63       -0.62      -0.66     Missed  -5.6​
 Jun. 30 2021  -0.49       -0.49      -0.58     Missed  -17.4
 ​​Mar.        -0.43       -0.42      -0.47     Missed  -10.8
 31 2021                                                
 Dec. 31 2020  -0.47       -0.47      -0.45     Beat    3.7​
 Sep. 30 2020  -0.43       -0.43      -5.25     Missed  -1,120
                                                        .9
 This summary was machine generated August 8 at 17:04 GMT.  All
figures in US dollars  unless otherwise stated